Navigation Links
Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Date:8/20/2007

SAN DIEGO, Aug. 20 /PRNewswire-FirstCall/ -- Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in therapeutic agents against bioactive lipids, reported that a standard panel of safety tests was recently completed with the humanized version of Sphingomab(TM), and the findings indicate no safety concern for systemic dosing of the antibody to humans.

Sphingomab, generated by Lpath's proprietary ImmuneY2(TM) platform technology, is a monoclonal antibody against the bioactive lipid S1P (sphingosine-1-phosphate). S1P has been well validated as a stimulator of angiogenesis (new blood-vessel growth), a process that has been strongly implicated in the pathology of both cancer and AMD.

The safety tests included cardiovascular studies in Cynomolgus monkeys as well as tests to evaluate the potential of the antibody to elicit the release of cytokines or an Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) reaction. The cardiovascular study included evaluation of the effect of humanized Sphingomab treatment on blood pressure, heart rate, and respiratory rate. The cardiovascular, cytokine release, and ADCC tests with humanized Sphingomab were all negative at doses or concentrations well above those expected to be needed in man to provide an anti-angiogenic action.

The panel of tests also included a pivotal multiple-dosing 28-day study in Cynomolgus monkeys. This study featured intravenous administration of humanized Sphingomab at doses as great as 100 mg/kg every three days for 28 days (10 total doses). Parameters monitored during this study included mortality, body weight, organ weight, clinical observations, ophthalmology, clinical pathology (hematology, clinical chemistry, coagulation, and urinalysis), and immune-phenotyping, both pre-treatment and on day 28 in all animals, and after one, two, three, and four weeks of recovery in a large sub- group of the animals.

No animal deaths occurred during the study. There were also no signific
'/>"/>

SOURCE Lpath, Inc.

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2008)...ir 11- and 12-year-olds from,meningitis, whooping ... ATLANTA, Aug 28 /PRNewswire-USNewswire/ -- The Ce...ational Center for Immunization and,Respiratory Di...ouncements,(PSAs) targeting the parents of pre-tee...he television and radio spots, part of CDC,s Pre-T...
(Date:8/27/2008)... Delaware, Montgomery,Philadelphia Counties, NOR...fter encouraging,results following the first night...ntal Protection will continue its efforts this eve...rne West Nile virus., Targeted aerial treatments ...n portions of Bucks, Delaware, Montgomery and Phil...
(Date:8/27/2008)...at The Children,s Hospital at, Montefiore Provid...and Specialty Services, ... Every Heart Condition, NEW YORK, Aug. 27 /PRNews...tefiore (CHAM) is bringing the medical miracle of ...owing the recent approval of its,transplant center...
(Date:8/26/2008)...fore Pharmaceuticals Inc.,presented data at the Se...,in Cancer in Washington, D.C., announcing the dis...hat demonstrate significant anticancer,activity in...lecular scaffold has been developed using,computat...kinase inhibitors,as well as isoform-selective sma...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 2Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 4Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Respiratory illnesses and dog bites a concern for travelers to China for 2008 Olympics 24669 1Respiratory illnesses and dog bites a concern for travelers to China for 2008 Olympics 24669 2Geecf 3A Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities 6825 1Geecf 3A Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities 6825 2MTBC First Medical Billing Company in the U S To Offer Automated Real time Adjudication of Claims 24663 1MTBC First Medical Billing Company in the U S To Offer Automated Real time Adjudication of Claims 24663 2April Stewart Joins OrthoSynetics 28TM 29 as Corporate Communications Manager 24657 1
... Rexahn,Pharmaceuticals, Inc. (OTC BB:RXHN), a bio... development, and commercialization of,innovative ...rders,sexual dysfunction and other unmet medical ...ncipal Investigator of Phase I clinical,trial of t...n),will present results of the clinical study at ...
...n Transplantation, HORSHOLM, Denmark, May 31, 2007...ces positive Phase I clinical results for,its tran...nto US,Phase II clinical trials for organ transpla...nounces positive results,from its Phase I clinical...aily tacrolimus tablet. , A series of Phase I tria...
Other Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...sed on Monday, a drug that aims to prevent preterm...e earliest preterm births//, the main cause of dea...deza's (NASDAQ:ADZA) drug, Gestiva, is a long-acti...progesterone and is awaiting federal approval. ...
...rts have been restarted in India after declaring i... egg shipment to Muscat.// Due to the bird flu ou...ries around the world had stopped importing eggs f...t under control successfully by the several steps ...
...e of vaccination has yielded a much-improved quali...ing and help in fighting// many infectious disease...owever been slow and painstaking have been so bene...nd eradication of infectious diseases. It was unfo...
... balance in the body is skewed up is called Hypona... other conditions and requires urgent// treatment.... that some of the symptoms caused by hyponatremia ...a, vomiting, fatigue, and headache. Other serious ...
Other Medicine News:Health News:Gestiva – the pre-term birth drug probed by FD 2Health News:‘Bird flu-free’ India resumes egg expor 2Health News:Remarkable Progress In Development Of Vaccines 2Health News:Remarkable Progress In Development Of Vaccines 3Health News:Remarkable Progress In Development Of Vaccines 4
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
Medicine Products: